Abstract Long-term (>7 years) duration of function of ovarian cortical tissue grafts in three patients who have had several successful pregnancies is encouraging and requires us to carefully examine the risk benefit analysis of this technique for our future patients. However, the success rate for ovarian cryopreservation is unclear as the denominator (the number of women in whom frozen-thawed ovarian tissue has been re-implanted) is unknown. There still remain many unknowns and much more research is required before ovarian transplantation can be considered standard practice. The ability of ovarian cryopreservation to preserve fertility for some young survivors of cancer is proven, but the indications for which patients should be offered this exciting new technology are not yet established. KEYWORDS: egg freezing, fertility preservation, menopause, ovarian cryopreservation, ovarian reserve With at least 18 pregnancies reported worldwide from orthotopic reimplantation of frozen-thawed ovarian cortex (Donnez et al., 2011) there is understandable and justified interest in this new technology as a means of fertility preservation for cancer patients. Silber (2012) have also extensively reported their experience of successful fresh ovarian transplantation in identical twins discordant for premature ovarian failure: to date 12 pregnancies and eight healthy babies have been reported from nine homozygotic transplants. The article by Andersen et al. (2012) in this issue of Reproductive BioMedicine Online describes three women who have experienced long-term duration of function of ovarian cortical tissue grafts. One woman underwent sterilizing cancer treatment and had frozen ovarian tissue transplanted, and two women underwent fresh ovarian tissue transplants. Remarkably, the function of the ovarian cortical strips has continued for more than 7 years in these three women, with the birth of eight healthy babies following a single graft per patient. The authors speculate that ''this new technique may not only provide a realistic hope for saving the fertility for young patients surviving cancer treatment that would otherwise render them sterile and menopausal, but also for expanding a woman's reproductive and hormonal lifespan long past its current limits''.
With at least 18 pregnancies reported worldwide from orthotopic reimplantation of frozen-thawed ovarian cortex (Donnez et al., 2011) there is understandable and justified interest in this new technology as a means of fertility preservation for cancer patients. Silber (2012) have also extensively reported their experience of successful fresh ovarian transplantation in identical twins discordant for premature ovarian failure: to date 12 pregnancies and eight healthy babies have been reported from nine homozygotic transplants. The article by Andersen et al. (2012) in this issue of Reproductive BioMedicine Online describes three women who have experienced long-term duration of function of ovarian cortical tissue grafts. One woman underwent sterilizing cancer treatment and had frozen ovarian tissue transplanted, and two women underwent fresh ovarian tissue transplants. Remarkably, the function of the ovarian cortical strips has continued for more than 7 years in these three women, with the birth of eight healthy babies following a single graft per patient. The authors speculate that ''this new technique may not only provide a realistic hope for saving the fertility for young patients surviving cancer treatment that would otherwise render them sterile and menopausal, but also for expanding a woman's reproductive and hormonal lifespan long past its current limits''.
Good news in medicine often travels fast and indeed this is an important case series, adding to our understanding of the potential of this technique. But, critical to assessment of this technique, the success rate for ovarian cryopreservation is unclear as the denominator (the number of women in whom frozen-thawed ovarian tissue has been re-implanted) is unknown. Andersen and colleagues state that ovarian activity has been demonstrated after every transplant: this may reflect publication bias, and it is also clear that not all grafts have resulted in a successful pregnancy (Greve et al., 2012) . Until a worldwide registry recording every case of ovarian transplantation is established it remains impossible to counsel women on the potential success rate of this procedure.
Other central issues include the safety and indications for what is an invasive procedure in women who will be, in the main, facing a life-threatening new diagnosis. Further research and clinical trials of ovarian cryopreservation are urgently required to define the place of this new technique and prove its safety. The majority of patients will be young adult women, competent to decide for themselves whether to pursue this option. It is also safe and feasible to collect ovarian tissue for freezing by laparoscopy under a general anaesthetic in pre-pubertal girls (Anderson et al., 2008; Jadoul et al., 2010) , for whom issues of understanding and consent are more complex. There have been no pregnancies reported following the re-implantation of ovarian tissue harvested pre-pubertally, although a very recent report (Poirot et al., 2012) describes heterotopic reimplantation of frozen-thawed ovarian tissue for pubertal induction in a patient who had a bone marrow transplant for sickle cell disease. The use of precious ovarian tissue to induce puberty or provide sex steroid replacement therapy is in our view a potential waste of a finite number of preserved oocytes. We consider that the harvested tissue should be reserved for preserving fertility when pregnancy is desired. Pubertal induction using sex steroids is well established and while there may be theoretical advantages in using ovarian tissue to provide a potentially more physiological pubertal induction, it is unclear that this will in fact be the case. The abnormal gonadotrophic environment may lead to a very different profile of follicle growth and hormone production than the normal gradual increase of physiological puberty, with delayed exposure to progesterone. As with all novel therapies, advantages and disadvantages need to be carefully considered and assessed.
For the cancer patient there remain significant concerns over the transplantation of frozen thawed tissue that may be contaminated with the original cancer, particularly in haematological cancers , and hence cause relapse of the original disease. We have personal experience of unexpected contamination of harvested ovarian tissue in a 12-year-old girl with apparently non-metastatic Ewings sarcoma of the T7 vertebra. It is imperative that harvested material is examined histologically (or by molecular biological techniques where specific markers are known) to exclude contamination by the original cancer as this would preclude reimplantation at a later date.
Risk assessment for fertility preservation
The majority of girls and young women treated for cancer will retain a window of opportunity for fertility. The pregnancy rate after ovarian tissue reimplantation should be compared with that in women who had tissue cryostored but not reimplanted: again few data exist but this control rate is often high (Anderson et al., 2008) . In an report of successful pregnancy after reimplantation, 15 of 21 women (71%) who had ovarian tissue stored but not replaced had natural pregnancies recorded (Andersen et al., 2008) , and in a longer-term follow-up study of women who had had an oophorectomy for fertility preservation before chemotherapy, >65% were having regular menstrual cycles (except where treatment involved stem cell transplant) and a very similar proportion had achieved a pregnancy without reimplantation of ovarian tissue (Schmidt et al., 2011) . Identification of those women at particular risk is therefore important. We recommend that all new young patients with cancer have a risk assessment performed for fertility preservation before treatment commences . At presentation the priority for the oncology team remains to make the correct tissue diagnosis, complete the staging investigations and with the consent of the patient enter them into a clinical trial if one is available. It remains important to discuss fertility preservation before treatment starts despite the understandable pressure to initiate treatment. However, discussing fertility preservation with children and their families is not generally within the expertise and knowledge base of oncologists. We believe that raising the issue of fertility preservation at the time of presentation can be construed as a positive discussion for the young patient.
However, it remains difficult to give an accurate prediction of the fertility prognosis for most patients. Radiotherapy to a field that includes the ovaries is likely to impair fertility in a dose dependent manner , and radiation to the pelvis may interfere with the ability of the uterus to maintain a pregnancy to term (Critchley and Wallace, 2005) . It is possible to estimate the radiation dose received by the ovary furthest away from the radiation field and this can be used to help provide a fertility prognosis. However it is not always possible to predict whether radiation treatment will be required at the outset in young patients with pelvic tumours, haematological malignancies or lymphoma.
Currently the most important factor in making an accurate assessment of the patient's ovarian reserve remains her age (Wallace and Kelsey, 2010 ) with a need to identify women with low ovarian reserve who it is assumed will be at increased risk of loss of fertility in the face of a given gonadotoxic treatment than a woman of the same age with a higher reserve. There is increasing interest in the measurement of anti-Müllerian hormone (AMH) as an indirect marker for ovarian reserve and now normal ranges through life have been described (Kelsey et al., 2011) . Nevertheless prediction of an individual's ovarian reserve remains difficult and unreliable. AMH is predictive of long-term ovarian function after chemotherapy in adult women (Anderson and Cameron, 2011) , and possibly also in girls (Brougham et al., 2012) , thus may be of value in assessing and advising women considering fertility preservation. Experimental data that allow the objective assessment of this are currently lacking. A further difficulty is sufficient time to set up the required laparoscopic ovarian collection procedure in the face of the need to start life saving treatment. The required interdisciplinary expertise is currently only available in a limited number of centres; while ovarian cryopreservation is probably best provided by a few centres in each country, this needs to be considered at a national level taking into account local practice and variations in regulatory environments.
How long can we expect ovarian grafts to function?
The duration of graft life in the linked report is greater than 7 years, but has generally been shorter in previous reports, cited therein. Clearly the length of time the grafts function will depend on many factors. Perhaps the most important relates to how many immature eggs survive the freeze/thaw and revascularisation process. If we make an assumption that one third of one ovary is transplanted into the patient (the proportion quoted in the linked report) and that during revascularisation two thirds of the immature eggs are lost (Baird et al., 1999; Demirci et al., 2001 ) then we can calculate how many immature eggs are likely to survive the freeze/thaw and revascularisation process to ensure that >1000 non-growing follicles (NGF) are successfully transplanted (the number present at the menopause: Faddy and Gosden, 1996; Wallace and Kelsey, 2010) . We have estimated that at age 36.9 years insufficient NGF will remain after cryopreservation to sustain ovarian function in 40% of the healthy population (Supplementary Figure 1) . Similarly at age 40 years we estimate that 60% of healthy women are unlikely to benefit from ovarian cryopreservation. These figures are based on the available very limited evidence, and are proposed as a starting point for future study and refinement.
The publication of these three case reports demonstrating long-term duration (up to 7 years) of ovarian function and several successful pregnancies is encouraging and requires us to carefully examine the indications and risk benefit analysis for our future patients. There still remain many unknowns and much more research is required before ovarian transplantation can be considered standard practice for reversing the menopause. The ability of ovarian cryopreservation to preserve fertility for some young survivors of cancer is proven, but the indications for which patients should be offered this exciting new technology are not yet established.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.rbmo.2012.06.008.
